

CASE OF THE MONTH

Diagnosis: Alternariosis

LONDON — Culture of a biopsy specimen revealed the presence of the ubiquitous fungus *Alternaria alternata*, and an indirect immunofluorescence assay found *Alternaria* antibodies in a titer of 1:640.

Histopathologic examination found a granulomatous infiltrate in the dermis, and a periodic acid-Schiff stain was positive for septated hyphomycetes.

Cutaneous alternariosis can result directly, via traumatic inoculation of the fungus into the skin, or secondarily after inhalation of the conidia and systemic spread to the dermis or epidermis, Dr. Mira Kadurina said at the 14th Congress of the European Academy of Dermatology and Venereology.

Histopathologic findings can include microabscesses or granulomatous formations in the dermis and subcutis.

Hyphal elements in the tissue may be branched, thick-walled filaments; spherical cells; or short chains of oblong cells,


explained Dr. Kadurina, who is with the Military Medical Academy in Sofia, Bulgaria.

This patient was not immunocompromised, but most cases of alternariosis have been reported in patients with malignancies, endocrine or autoimmune disease, a history of organ transplantation, or immunosuppressive therapy. More than half of cases have been seen in patients undergoing systemic corticosteroid treatment, Dr. Kadurina said.

The patient received three 14-day courses of itra-

conazole, 400 mg/day, over a period of 3 months, and responded well clinically. The antibody titer decreased to 1:80. Hyperpigmented scarring remained, but pain and pruritus resolved and no new lesions subsequently appeared.

—Nancy Walsh



Granulomatous infiltrate was present in the dermis.

Brevoxyl®-4 Creamy Wash (benzoyl peroxide 4%)


Brevoxyl®-8 Creamy Wash (benzoyl peroxide 8%)

ACNE WASH FOR TOPICAL USE

Rx only Rx only

DESCRIPTION

Brevoxyl-4 Creamy Wash and Brevoxyl-8 Creamy Wash are topical preparations containing benzoyl peroxide as the active ingredient. Brevoxyl-4 Creamy Wash and Brevoxyl-8 Creamy Wash contain: 4% and 8% Benzoyl Peroxide, respectively, in a lathering cream vehicle containing Cetostearyl Alcohol, Cocamidopropyl Betaine, Corn Starch, Dimethyl Isosorbide, Glycerin, Glycolic Acid, Hydrogenated Castor Oil, Imidurea, Methylparaben, Mineral Oil, PEG-14M, Purified Water, Sodium Hydroxide, Sodium PCA, Sodium Potassium Lauryl Sulfate, Titanium Dioxide. The structural formula of benzoyl peroxide is:



CLINICAL PHARMACOLOGY

The exact method of action of benzoyl peroxide in acne vulgaris is not known. Benzoyl peroxide is an antibacterial agent with demonstrated activity against *Propionibacterium acnes*. This action, combined with the mild keratolytic effect of benzoyl peroxide is believed to be responsible for its usefulness in acne. Benzoyl peroxide is absorbed by the skin where it is metabolized to benzoic acid and excreted as benzoate in the urine.

INDICATIONS AND USAGE

Brevoxyl-4 Creamy Wash and Brevoxyl-8 Creamy Wash are indicated for use in the topical treatment of mild to moderate acne vulgaris. Brevoxyl-4 Creamy Wash and Brevoxyl-8 Creamy Wash may be used as an adjunct in acne treatment regimens including antibiotics, retinoic acid products, and sulfur/salicylic acid containing preparations.

CONTRAINDICATIONS

Brevoxyl-4 Creamy Wash and Brevoxyl-8 Creamy Wash should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients in the product.

PRECAUTIONS

General — For external use only. Avoid contact with eyes and mucous membranes.
AVOID CONTACT WITH HAIR, FABRICS OR CARPETING AS BENZOYL PEROXIDE WILL CAUSE BLEACHING.
Carcinogenesis, Mutagenesis, Impairment of Fertility — Based upon all available evidence, benzoyl peroxide is not considered to be a carcinogen. However, data from a study using mice known to be highly susceptible to cancer suggest that benzoyl peroxide acts as a tumor promoter. The clinical significance of the findings is not known.
Pregnancy: Category C — Animal reproduction studies have not been conducted with benzoyl peroxide. It is also not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzoyl peroxide should be used by a pregnant woman only if clearly needed.
Nursing Mothers — It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzoyl peroxide is administered to a nursing woman.
Pediatric Use — Safety and effectiveness in children below the age of 12 have not been established.

ADVERSE REACTIONS

Contact sensitization reactions are associated with the use of topical benzoyl peroxide products and may be expected to occur in 10 to 25 of 1000 patients. The most frequent adverse reactions associated with benzoyl peroxide use are excessive erythema and peeling which may be expected to occur in 5 of 100 patients. Excessive erythema and peeling most frequently appear during the initial phase of drug use and may normally be controlled by reducing frequency of use.

DOSAGE AND ADMINISTRATION

Shake well before using. Wash the affected areas once a day during the first week, and twice a day thereafter as tolerated. Wet skin areas to be treated; apply Brevoxyl-4 Creamy Wash or Brevoxyl-8 Creamy Wash, work to a full lather, rinse thoroughly and pat dry. Frequency of use should be adjusted to obtain the desired clinical response. Clinically visible improvement will normally occur by the third week of therapy. Maximum lesion reduction may be expected after approximately eight to twelve weeks of drug use. Continuing use of the drug is normally required to maintain a satisfactory clinical response.

HOW SUPPLIED

Brevoxyl-4 Creamy Wash is supplied in 170.1 g (6.0 oz) tubes NDC 0145-2474-06.
 Brevoxyl-8 Creamy Wash is supplied in 170.1 g (6.0 oz) tubes NDC 0145-2484-06.

Store at controlled room temperature, 15°-30°C (59°-86°F).

¹In vitro experiment.
 Clinical significance has not been established.
²US Patent No. 6,433,024.

References: 1. IMS Health, September 2005.
 2. Data on file, Stiefel Laboratories, Inc.
 3. Savoie PM, Whitbeck N, Fraser J. An in vitro kill rate study against *P. acnes* comparing four benzoyl peroxide washes. Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC.

Brevoxyl is a registered trademark of Stiefel Laboratories, Inc. Research in Dermatology is a trademark of Stiefel Laboratories, Inc. ©2006, Stiefel Laboratories, Inc. BVX-10-2006-USA 87384 Rev.0904



Stiefel Laboratories, Inc.
 Coral Gables, FL 33134

Advice Offered for Common Office Dilemmas

BY BETSY BATES

Los Angeles Bureau

LOS CABOS, MEXICO — Every community dermatologist dreads the phrase, "Oh, by the way ..."

It comes, all too often at the end of a harried day, spoken by the young mother with rosacea who waits until the last millisecond to point out her teenager's acne and her 8-year-old's hair loss.

To survive, clinicians often come up with creative, effective, and amusing strategies to cope with real-world dilemmas, but they rarely sit down and compare notes.

That's why Dr. Michael A. Greenberg, a dermatologist in Elk Grove Village, Ill., codirected a workshop entitled, Bring Us Your Office Problems, at the annual meeting of the Noah Worcester Dermatological Society.

The problems raged, but solutions abounded at the lively session. Here are some of the more thorny issues presented, as well as the attendees' suggestions.

"Oh, By the Way . . ."

All dermatologists who attended the session said they stop what they are doing and take a look only if the last-minute issue involves a black or otherwise suspicious lesion. If not, they delay. Some explain to patients that medicolegal rules require that any visit be documented in a chart. They send the patient and his or her entourage back to the front desk so a chart can be established or retrieved, and then offer to work the new patient into the schedule.

"It may be 5 minutes; it may be an hour," Dr. Charles Zuger of Chicago tells his patients.

Dr. Lee J. Vesper of Cincinnati emphasized the complexity of what may seem like a simple issue: "There are 52 kinds of hair loss. I need to take a good history."

Dr. Greenberg quipped, "I don't take quick looks. I only take careful looks."

"I Have a List"

"Carpe registrar: Seize the list," advised Dr.

Alan M. Ruben of Wheeling, W.Va.

The strategy has two rationales. First, patients often begin with the least important issue first. Second, many of the items on the list may be related to one condition, so reviewing the list may aid in diagnosis and treatment.

If the list is long and complex, prioritize the problems and assign the rest to a new appointment, attendees suggested.

"Why Did I Have to Wait So Long?"

The worst horror story came from Dr. Zuger, who once faced a revolution in his waiting room when four or five patients united to demand that he come out to explain the "obscene" amount of time they had been waiting.

Many dermatologists said they have had to revise the way they schedule to alleviate waiting times. Dr. Stuart M. Brown of Dallas suggested stretching most appointment slots to 30 minutes and leaving open the last hour of the morning and the afternoon.

"I think it's a sin to keep people waiting a long time, but then act rushed," said Dr. Ruben. As he enters a room, he apologizes, first thing.

Dr. Greenberg keeps a plaque in his waiting room that explains delays, noting that emergencies arise and dermatologic cases sometimes prove to be unexpectedly complex. He also reminds people that they'll receive special attention on the day they need it.

Dr. Brett M. Coldiron of Cincinnati said he reduced his waiting times by dropping his two worst-paying insurance carriers. He also uses his lunch hour to catch up with charting and phone calls.

"Patients don't wait; charts do," he said.

"Can You Remove an Irritated Skin Tag?"

Most dermatologists remove a few skin tags or benign lesions for free. If there are many, and the patient wants them all off, some physicians explain that insurance won't cover their removal and ask if the patient wants to pay cash.

Dr. Ruben asks the patient to sign a note that goes into the chart and to the insurance company. It states the following:

- ▶ The patient has been reassured all lesions are benign and normal.
- ▶ The patient has identified lesions that are symptomatic.
- ▶ Only these symptomatic lesions were treated at the patient's request.

Given this information, some companies reimburse for their removal, he said.

What Bill?!

Sometimes a patient owes a significant amount and it becomes clear that they never intend to pay. Dr. Greenberg offered a possible solution: forgiveness of the debt. The physician writes off the debt. A Form 1099 is issued and referred to the Internal Revenue Service, which will demand that the debtor pay social security, Medicare fees, and taxes on the amount.

Rep Raps

Dermatologists voiced several complaints about pharmaceutical representatives, especially those who show up on a busy day to hype a "third-generation, me-too drug."

Many physicians require that reps schedule an appointment for routine business. One requests "payment" for the visit in the form of a donation to a charity. Another has salespeople wait in a "rep room" until the physicians have a break in their schedules.

Dr. Peter J. Muelleman of Independence, Mo., will speak to reps who show up unannounced, but only for a "socially appropriate amount of time—not 10 minutes."

"They don't have to buy lunch," he explained. "The staff knows which ones I want to see."

Virtually all of the dermatologists said they appreciate pharmaceutical samples, which enable them to treat Medicare patients who would do best on an expensive drug, to see if a patient reacts to a drug before prescribing it, and to conduct split-face studies to see which of two agents is best for an individual patient. ■